Compound 1 Synthesis for Selective Late Sodium Current Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions associated with aberrant sodium ion channel function, such as epilepsy and cardiac disorders, are inadequate in modulating the late sodium current (INaL), leading to electrical and contractile dysfunction.
Innovation Solution
Development of pharmaceutical compositions containing Compound 1, administered in specific dosages, to selectively modulate sodium channel activity and treat conditions like epilepsy, cardiac disorders, and other neurological and psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for conditions associated with aberrant sodium ion channel function, then general symptom management is achieved, but modulation of late sodium current (INaL) is inadequate leading to electrical and contractile dysfunction
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of Compound 1, specifically modifying the pyridyl-triazolopyrazine core with fluorinated ether substituents to enhance sodium channel binding affinity and selectivity for modulating INaL current
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining Compound 1 with excipients and formulation components to achieve optimal bioavailability, stability, and therapeutic efficacy for treating sodium channel-related disorders
2Reliability
If pharmaceutical compositions containing Compound 1 are administered to selectively modulate sodium channel activity, then therapeutic benefits for neurological and cardiac conditions are achieved, but the complexity of the synthesis process increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis of Compound 1 into distinct modular steps: preparing the difluoroacetyl chloride intermediate, reacting with the triazolopyrazine core, and final purification, allowing each step to be optimized independently
Solution Approach 2:
The patent uses intermediary compounds such as the difluoroacetyl chloride and protected triazolopyrazine intermediates that facilitate the overall synthesis by enabling selective transformations and improving reaction efficiency
Data Source
AI summary
The present invention is directed to, in part, a method of making (3-[cyclopropylethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridyl]-[1,2,4]triazolo[4,3-α]pyrazine (Compound 1);comprising reacting key synthetic intermediates and providing methods of making the same.